Rep+ will better enable orthopedic MedTech Representatives to provide remote support and Clinician training, and is now available to hospitals via the Avail telepresence platform

WEST CHESTER, Pa., October 19, 2023 (Newswire.com) - ORtelligence, a healthcare technology company designing and launching software that ensures surgical teams have the right information, equipment, and support for optimal patient outcomes, is proud to unveil its latest innovation, Rep+^TM. Rep+ is a Software-as-a-Service (SaaS), AI-enabled surgical support software application designed to revolutionize the surgical process and enhance patient care by facilitating a medical professional's efforts to deliver support, training and drive efficiency for surgical teams. Rep+ is now available commercially to MedTech companies to be used for product training, and for use in hospitals via the Avail telepresence platform.

Rep+ is a groundbreaking AI-enabled software application that allows orthopedic MedTech representatives to interact remotely with the onsite surgical team via a custom user interface that displays all the tools and implants required for surgical cases. Rep+ is designed to ensure that the product expertise of MedTech representatives is accessible in the operating room even when they can't be physically present, by enabling the representative to remotely guide the surgical support team, reducing potential for equipment confusion and potentially shaving minutes off a procedure. 

“This technology is aligned with ORtelligence's core mission: to deliver cutting-edge software that ensures surgical teams have the right information, equipment, and support for optimal patient outcomes,” stated Tim Donnelly, CEO of ORtelligence. “By harnessing real-time data capture and deep machine learning, the platform offers a suite of tools for case preparation, remote support, inventory management, and real-time analytics. Rep+ is poised to make a significant impact on surgical venues by facilitating collaboration that can reduce waste, cut costs, and enhance the quality of care.” 

MedTech companies who wish to use Rep+ may purchase the software to train their teams allowing junior representatives to familiarize themselves with case equipment layouts and usage more quickly. In operating rooms, Rep+ will be available through an integration with the Avail telepresence platform. The Avail console in the operating room contains high-definition cameras, audio, edge-computing and a connection to the cloud, along with a large screen so that remote users can interact with the onsite surgical team.

Using Avail, MedTech representatives can log into a procedure remotely and use the video cameras and telestration features on the Avail console to interact visually and audibly with surgical teams. The MedTech representatives can use the Rep+ software locally while sharing the application through Avail to the surgical team on the large Avail console monitor, sharing visuals of surgical trays specific to that case and providing information about the instruments to the surgical staff.

One of Rep+’s unique attributes is its patented user interface that shows users the required implants and tools for every step of a surgical procedure. The interface simplifies instrument identification, instructions for use, virtual expert support, and implant/supply consumption tracking, making it an indispensable tool for surgical support teams.

“We are very excited about the partnership with ORT and the opportunity for Avail's orthopedic MedTech customers to access Rep+ to support their surgical teams,” stated Daniel Hawkins, Avail CEO. “The future of healthcare looks smarter and more informed because of the innovation going on in software, and with Avail, surgical teams and MedTech companies can leverage efficiencies, data and knowledge that will be gained from Rep+ and other software applications that will be available on the Avail platform in the future, without adding more hardware to the operating room.”

ABOUT ORTELLIGENCE

Founded in 2018 by industry experts and world-class surgeons, ORtelligence is dedicated to revolutionizing healthcare by optimizing the surgical process through advanced technology. The company's mission is to improve the surgical process, resulting in reduced waste, improved cost management, streamlined surgical procedures, and enhanced patient care.

For more information about Rep+ and ORtelligence's revolutionary contributions to healthcare, please visit www.ortelligence.com.

Contact Information:
Steve Pirone
Vice President Client Success
[email protected]
484-467-2158


Original Source: ORtelligence Introduces Rep+TM, an AI-Enabled Surgical Support Software Application

A new study shows the combination of sustained acoustic medicine and platelet-rich plasma provides better outcomes, reinforcing clinical research on the efficacy of long-duration ultrasound.

TRUMBULL, Conn., October 19, 2023 (Newswire.com) - Elite athletes regularly use platelet-rich plasma (PRP) injections for soft tissue healing without surgery or steroids. A new study shows that athletes return to play more quickly, with less pain and better overall outcomes, when treated with a combination of PRP and ZetrOZ Systems’ sustained acoustic medicine (sam®) technology than with PRP alone.  

The study, published in Orthopedic and Muscular System: Current Research¹ in August 2023, examined the cases of 35 elite college-age football and track athletes with grade II hamstring strains, quadriceps strains, or patellar tendinopathy, commonly called “jumper’s knee.” None of the patients’ injuries had responded to conservative treatment after one week.

Athletes often use PRP to enhance healing from soft tissue injuries and reduce the need for surgical interventions, corticosteroids, and non-steroidal anti-inflammatory drugs (NSAIDs). Long-duration ultrasound treatment is becoming a common treatment for soft-tissue injuries, with many studies documenting its effectiveness in speeding recovery.

Researchers divided the athletes into two groups, with half receiving the PRP treatment alone and half receiving both PRP injections and long-duration ultrasound treatment with the ZetrOZ sam® 2.0 wearable ultrasound unit for four hours daily for two weeks.

At the end of the treatment period, the athletes who received both PRP and ZetrOZ sam® long-duration ultrasound showed better outcomes than those who received only PRP:

• Return to play (RTP) was 21.33 days faster with sam® and PRP compared to PRP alone. (p < 0.0001)  
• sam® and PRP decreased mean pain scores (NRS) by 0.88 points compared to PRP alone. (p = 0.0086)  
• sam® and PRP increased the global rating of change (GROC), an overall health improvement scale with a range of –7 to 7, by 1.28 points compared to PRP alone. (p < 0.0001)

This new study builds on a body of more than 40 studies, including 20 level I-V clinical research studies, randomized-placebo-controlled trials, and other publications confirming the efficacy of ZetrOZ Systems’ technology in treating back pain, arthritis pain, and strain injuries of tendons and ligaments, and its ability to improve recovery, range of motion, and strength.

“We’re pleased to see yet another study that confirms that our sam® wearable ultrasound unit accelerates tissue healing, relieves pain and helps people return to doing what they love to do,” said George K. Lewis, Ph.D., founder, president, and CEO of ZetrOZ Systems. “We’re especially pleased to see a study demonstrating that sustained acoustic medicine system facilitates and enhances the ability of other therapies, in this case, a regenerative medicine therapy like PRP.”

The study’s authors note that the improvements are significant in many ways: “A protracted RTP can have deleterious effects on the athlete’s physical and behavioral health, resulting in poor academic performance, affecting future athletic opportunities, and negatively impacting their team. Thus, reducing downtime while ensuring players are fully capable of performing is vital.”

The researchers concluded: “Our findings suggest that patients being treated with PRP therapy for healing a soft tissue injury may receive additional benefits with the addition of 14-day Long Duration Ultrasound therapy. The combination of PRP+LDU therapy provides a significant reduction in time to return to sport without impacting the long-term durability of the soft tissue. It increases pain reduction and overall health improvement for patients recovering from a sport-related injury. Non-invasive LDU therapy provides a valuable tool to expedite tissue regeneration and should be considered by practitioners to augment regenerative medicine approaches such as PRP.”

To learn more, visit www.samrecover.com.

1) Krystofiak J, Bruins J, Bates E, Kummer J (2023) Long Duration Ultrasound Combined with Platelet-Rich Plasma Injection for Return to Sport after Soft Tissue Injury: A Single Center Study. Orthop Muscular Syst. 12:366.

About ZetrOZ Systems

ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of +46 patents and is the exclusive manufacturer and developer of the sam® product line, which is designed for the treatment of acute and chronic musculoskeletal conditions.

Contact Information:
Maria Penaloza
[email protected]


Original Source: Athletes Heal Better, Return to Play Sooner With ZetrOZ Systems’ sam Ultrasound Treatment and PRP Than With PRP Alone

Investment enables ACU-Serve to expand its service offerings, accelerate technology development and pursue strategic acquisition opportunities

PHILADELPHIA, October 19, 2023 (Newswire.com) - ACU-Serve Corp. (“ACU-Serve” or the “Company”), a leading provider of end-to-end revenue cycle management, announced today that it has received a majority growth investment from Lovell Minnick Partners LLC (“LMP”), a private equity firm focused on investments in financial services, business services, and financial technology companies. The Company will remain independent and will continue to be led by its current management team, including Founder and Chief Executive Officer Jim Knight. This strategic partnership will enable ACU-Serve to expand its suite of comprehensive solutions, accelerate technology innovation, and continue its successful acquisition strategy. LMP will invest from its affiliated funds, Lovell Minnick Equity Partners V LP and Lovell Minnick Equity Partners V-A LP. Terms of the transaction were not disclosed.

Founded in 1993, ACU-Serve is a leader in revenue cycle management for healthcare providers focused on post-acute, home-based care, including the home medical equipment (“HME”), durable medical equipment (“DME”), and home infusion industries. The Company’s comprehensive service portfolio encompasses intake, revenue recovery, accounts receivable management, consulting, compliance, cash posting, and analytics, all of which have been meticulously crafted to mitigate claim denials, expedite claims processing, and optimize revenue collection. ACU-Serve’s technology-enabled platform includes ACU-Insight, a proprietary business intelligence platform consisting of Claims, Clarity and Smartsheet, a workflow and productivity solution; together, these tools combine industry expertise with advanced analytics to provide clients with real-time, actionable insights into their entire revenue cycle operation to ensure best-in-class service quality. 

“We share a common goal of not only growing our business but also strengthening our relationships with our clients,” said Jim Knight, CEO of ACU-Serve. “With LMP’s track record of success in the industry, we are confident that together, we will provide our clients with even greater value, reinforcing our commitment to customer service and technology innovation. We are thrilled to find a partner who supports our vision for growth and one who brings additional resources to help us accomplish our objective of helping more clients, who, in turn, provide critical care to patients in need.”

“We have a long track record of successful partnerships with high growth, technology-enabled companies run by proven, dynamic management teams with client-first attitudes,” said Brad Armstrong, Partner at LMP. “We look forward to partnering with Jim and the management team to expand service offerings, enhance technology capabilities, and pursue strategic acquisitions to complement its organic growth trajectory.”

In conjunction with the investment from LMP, ACU-Serve appointed former President of Experian Health, Scott Bagwell, and former CEO of Savista, Brenda Cline, to its Board of Managers. Scott Bagwell brings over 30 years of experience across multiple healthcare verticals, including clinical, pharmacy, payments, and RCM. His current and former board positions include CORL Technology, Genesis AHC, EnableComp, and Verisys Corporation. Brenda Cline brings over 30 years of experience leading healthcare financial operations, large-scale revenue cycle operations, strategic planning, and process optimization. She has held senior executive leadership roles at HCA, Parallon, nThrive, and Savista.

Benesch Friedlander Coplan & Aronoff LLP served as legal advisor to ACU-Serve and Morgan, Lewis & Bockius LLP served as legal advisor to LMP. Citizens M&A Advisory served as financial advisor to ACU-Serve and Baird served as financial advisor to LMP. 

+++

About ACU-Serve

ACU-Serve empowers post-acute, home-based healthcare providers to gain complete visibility and full transparency into their financial health through the Company’s proprietary technology platform, team of dedicated professionals, and wealth of experience spanning decades. ACU-Serve takes a strategic partnership approach to help clients increase cash flow and maintain compliance with ever-changing regulations, enabling them to focus on delivering high-quality customer service. Through an end-to-end services and technology offering, ACU-Serve addresses healthcare provider needs throughout all aspects of the revenue cycle, complete with a services and analytics hub to provide real-time financial and operational insights.

To learn more about ACU-Serve, visit www.acuservecorp.com.

About LMP

Lovell Minnick Partners is a private equity firm with a 20+ year track record of partnering with growth-oriented companies. We leverage our deep sector experience and broad network of strategic advisors to help founders scale their companies at an accelerated pace. LMP collaborates with management teams to achieve long-term success and value creation through organic growth and strategic acquisitions. Since our inception in 1999, we have raised approximately $4.75 billion of committed capital, invested in over 50 unique platform companies, and completed over 175 add-on acquisitions. LMP targets growth-oriented, middle-market companies, with a particular focus on companies in the financial services, business services, and financial technology sectors.

Media Contact

LMP
Ben Howard
[email protected]

ACU-Serve
Kat Allen 
[email protected]

Contact Information:
Ben Howard
[email protected]

Kat Allen
[email protected]
330-714-2274


Original Source: ACU-Serve Receives Growth Investment From Lovell Minnick Partners

Comprehensive National Survey Also Showed Overwhelming Support for Better Healthcare Equity and Removing Barriers to Imaging Care

WASHINGTON, October 19, 2023 (Newswire.com) - A comprehensive new national survey conducted by the Radiology Business Management Association's Radiology Patient Action Network (RPAN) and the Medical Imaging & Technology Alliance (MITA) indicates strong opposition among Americans to proposed cuts in Medicare reimbursement rates for healthcare providers.

The poll found that 76% of respondents disagreed with reducing payments to doctors and other healthcare providers for Medicare services. Additionally, 53% agreed that cutting payments to providers is equivalent to cutting Medicare itself. Forty-nine percent were extremely concerned and 31% were somewhat concerned about potential reimbursement cuts to doctors.

"This data clearly shows that the American people do not support cuts to Medicare providers that could reduce access to quality care," said Bob Still, Executive Director of RPAN. "We urge Congress and the Administration to listen to the people and reconsider these proposed reimbursement reductions that could seriously impact patient care across the country."

There was also overwhelming opposition to paying healthcare providers less for imaging services like mammograms, with 74% disagreeing with proposed cuts. Approximately 73% agreed that the government should be investing more in lifesaving diagnostic imaging.  

"Cutting reimbursements now would only further damage providers that are still recovering from COVID-19," said Patrick Hope, Executive Director of MITA. "Ensuring adequate funding for imaging services that detect diseases early and save lives needs to remain a top priority."

The principle of healthcare equity also resonated strongly. About 76% believed that all Americans deserve access to optimal healthcare regardless of non-medical factors. Many had experienced barriers to imaging care over the past two years.

"Lawmakers need to keep equity in mind and avoid changes that might impede access," said Still. "Investing in critical services while promoting healthcare equity should be priority number one." 

The wide-ranging poll was conducted from Oct. 11-13 among 1,200 Americans. It has a +/- 2.8 percentage point margin of error. RPAN and MITA urge Congress and the Administration to fully consider public opinion and avoid imposing cuts that could hurt healthcare providers and Medicare patients. Investing in critical services like diagnostic imaging while promoting healthcare equity should be central aims of policymakers.

About RBMA

The Radiology Business Management Association (RBMA) is an industry-leading organization of more than 2,100 professionals who focus on the business of radiology. RBMA members support diagnostic imaging, interventional radiology and radiation oncology providers in the full spectrum of practice settings. RBMA connects members nationwide to valuable information, education, and practice-related resources and serves as an authoritative industry voice on behalf of shared member interests.

About MITA

The Medical Imaging & Technology Alliance (MITA), a division of the National Electrical Manufacturers Association (NEMA), is the leading trade association representing the manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound devices. MITA represents companies whose sales make up more than 90 percent of the global market for advanced imaging technologies and strives to promote innovation, protect patient safety, and establish industry standards.

Contact Information:
Will Sweet
RBMA
[email protected]


Original Source: New RPAN and MITA Survey Shows Overwhelming Public Opposition to Proposed Medicare Cuts

Infinx Healthcare is named a Top 10 Vendor for RCM Software and is Shortlisted for their Predictive Analytics and Robotic Process Automation.

NEW YORK, October 19, 2023 (Newswire.com) - The healthcare IT research firm Black Book Research has named Infinx Healthcare as a top 10 Vendor for the Revenue Cycle Management Software and shortlisted them for End-to-End RCM Software and Predictive Analytics & Robotic Process Automation for 2023.

Black Book Research surveyed 1,100 health system financial managers on their experiences using revenue cycle management software solutions. Their team of analysts looked at customer satisfaction, performance, return on investment and more. 

Their research identified Infinx among the top 10 RCM software solutions for large hospitals and organizations and shortlisted them for small to midsize hospital chains. Infinx was also shortlisted for their Predictive Analytics & Robotic Process Automation for 2023.

According to Black Book Research methodology, top-10-ranked vendors and advisors must have a minimum of five unique clients represented. Broad categories require:

• Minimum of 20 unique client ballots
• Vendors, associates, consultants and advisors with over 20 unique client votes are eligible for top-10 rankings and are assured to have highest confidence and lowest variation. 
• Confidence increases as more organizations report on their outsourcing vendor. 
• Data reported in this form are shown with a 95 percent confidence level (within a margin of 0.25, 0.20 or 0.15, respectively).

Infinx Healthcare is a leading technology-enabled revenue cycle solutions provider. Earlier this year, it was also recognized as a Sample Vendor for a second year in a row for Intelligent Prior Authorization in the Gartner Hype Cycle for US Healthcare Payers in 2023.

Jaideep Tandon, Chairman and CEO of Infinx, said this industry-wide recognition will help healthcare providers with due diligence as they begin researching technologies for their next investment cycle. “This survey results from feedback from hospitals and CIOs who have worked with Infinx or have heard about us from their peers. They know what works and doesn’t work, so these recommendations matter,” says Tandon.

Infinx was recognized in two categories for RCM software and in one category for Predictive Analytics & Robotic Process Automation for its deep industry expertise, scalable processes and technology for revenue cycles.

Infinx’s Healthcare Revenue Cloud platform leverages a suite of customizable solutions that cover the entire revenue cycle, which includes help with eligibility verification, enhanced benefits checks, prior authorization, referral management, document capture, credentialing, coding, charge capture optimization and claims and denials management coding. These solutions are powered by AI, automation, workflow and workforce allocation technology, integrations and analytics.

Infinx clients have seen reduced staff 70-90 percent workload processing prior authorizations, 2 to 5 percent of their net patient revenue uplift and 20 percent above their net new collections by leveraging their technology.

“The healthcare system is full of complexities, but when hospitals and CIOs leverage advanced technology, it suddenly becomes more manageable. Workflows become more productive and revenue streams are increased with the help of these solutions,” said Tandon.

Healthcare groups interested in learning more can schedule a demo by clicking here: www.infinx.com/request-a-demo.

About Infinx Healthcare

Infinx Healthcare works closely with providers to overcome their revenue cycle challenges by leveraging automation and intelligence to increase reimbursements for patient care delivered. Their Healthcare Revenue Cloud technology platform optimizes the payment lifecycle by leveraging AI, automation, analytics, integrations and intelligent workforce management. 

Contact Information:
Mark Macias
[email protected]


Original Source: Black Book Research Names Infinx Healthcare as a Top 10 Vendor for RCM Software and Shortlists Their Predictive Analytics & Robotic Process Automation for 2023